Eli Lilly has become the first pharmaceutical company to reach a $1 trillion valuation, driven by surging demand for its weight-loss and diabetes drugs Mounjaro and Zepbound, reported Reuters (22 Nov 2025) Strong supply chains, rapid manufacturing scale-up, and high clinical efficacy helped Lilly overtake Novo Nordisk in prescription volume. The company now trades at premium tech-like valuations as its obesity portfolio fuels over half its $17.6bn quarterly revenue. Analysts expect continued growth, boosted by upcoming oral drug orforglipron. Investors increasingly view Lilly as a high-growth leader in the booming $150bn obesity-drug market.